Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Liminatus Pharma ( (LIMN) ) has provided an announcement.
On July 16, 2025, Liminatus Pharma, Inc. entered into a settlement agreement with Alta Partners, LLC, where the company agreed to issue 350,000 shares of its common stock in exchange for the cancellation of 1,000,000 warrants held by Alta Partners. This strategic move, involving no commission or remuneration, reflects Liminatus Pharma’s efforts to manage its equity structure and could have implications for its stock valuation and investor relations.
More about Liminatus Pharma
Average Trading Volume: 334,519
Technical Sentiment Signal: Sell
Current Market Cap: $145.4M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.